Daily Stock Analysis, LIVN, LivaNova PLC, priceseries

LivaNova PLC. Daily Stock Analysis
Stock Information
Open
76.50
Close
73.72
High
76.50
Low
73.52
Previous Close
76.56
Daily Price Gain
-2.84
YTD High
87.84
YTD High Date
Jan 5, 2022
YTD Low
68.68
YTD Low Date
Jan 28, 2022
YTD Price Change
-13.27
YTD Gain
-15.25%
52 Week High
93.89
52 Week High Date
Nov 5, 2021
52 Week Low
68.68
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-6.52
52 Week Gain
-8.13%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 26. 2017
69.02
Oct 17. 2017
74.03
15 Trading Days
7.26%
Link
LONG
Jul 23. 2018
105.00
Sep 4. 2018
123.90
30 Trading Days
18.00%
Link
LONG
Nov 11. 2019
74.32
Dec 3. 2019
82.00
15 Trading Days
10.33%
Link
LONG
Jul 10. 2020
51.51
Jul 28. 2020
55.83
12 Trading Days
8.40%
Link
LONG
Sep 30. 2020
45.21
Oct 20. 2020
53.74
14 Trading Days
18.87%
Link
LONG
Dec 2. 2020
53.28
Dec 30. 2020
65.18
19 Trading Days
22.33%
Link
LONG
Apr 5. 2021
76.48
May 4. 2021
82.40
21 Trading Days
7.74%
Link
Company Information
Stock Symbol
LIVN
Exchange
NasdaqGS
Company URL
http://www.livanova.com
Company Phone
4402033250662
CEO
Damien McDonald
Headquarters
-
Business Address
20 EASTBOURNE TERRACE, LONDON, UNITED KINGDOM W2 6LG
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001639691
About

LivaNova Plc is a global medical technology company specializing in the areas of Cardiac Surgery, Neuromodulation and Cardiac Rhthym Management. The company was founded on October 19, 2015 and is headquartered in London, the United Kingdom.

Description

LivaNova PLC, a medical technology company, design, develops, manufactures, and sells therapeutic solutions worldwide. It operates in three segments: Neuromodulation, Cardiac Surgery, and Cardiac Rhythm Management. The Neuromodulation segment designs, develops, and markets vagus nerve stimulation (VNS) therapy system, an implantable device for the treatment of drug-resistant epilepsy and treatment-resistant depression, as well as develops transcutaneous VNS devices. This segment serves neurologists, neurosurgeons, hospitals and healthcare systems, and government health departments. The Cardiac Surgery segment develops, produces, and sells cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves primarily for perfusionists and cardiac surgeons. The Cardiac Rhythm Management segment develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failures. This segment offers implantable cardiac pacemakers, cardioverter defibrillators, cardiac resynchronization therapy devices, and patient management tools primarily for electrophysiologists, implanting cardiologists, heart failure specialists, and cardiac surgeons. This segment also develops VITARIA systems for the treatment of chronic heart failure. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.